界面新闻记者 |陈杨界面新闻编辑 |谢欣近两年,国内越来越多创新药公司依靠产品销售收入,而非一次性BD(商务拓展)交易实现盈利或经调整利润为正。其中,一类公司通过新药出海,在商业回报效率更高的欧美市场获利,如百济神州、和黄医药。另一类则靠大单品新药率先在国内上市,占据国内市场,如艾力斯。当下,“宣布实现盈利”的创新药公司再添一员。3月26日晚间,信达生物公布2024年年报。当期,公司营收94.22...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.